Skip to main content
. Author manuscript; available in PMC: 2014 Oct 17.
Published in final edited form as: Oncogene. 2012 Jan 16;31(43):4609–4618. doi: 10.1038/onc.2011.606

Figure 7. NRG1 is required for Notch1-mediated melanoma cell growth.

Figure 7

A) Relative growth of WM266-4 cells after Notch1 knock down (shN1-2) at four days post treatment with recombinant NRG1 or vehicle control. The growth recovery of shN1-2 cells treated with recombinant NRG1 is statistically significant with respect to vehicle treated shN1-2 cells (p<0.001, Student's t test). B) Western blot analysis on WM266-4 cells for Notch1-TM , phospho- and total-Akt and p27Kip1. β-actin was used as loading control. C) Growth assay on V2387 cells expressing a control vector (pLM) or active Notch1 (NIC) and further infected with either a shRNA control (shGFP) or shNRG1-3. D) Western blot analysis on V2387 cells decribed in C for Notch1-TM , phospho- and total-Akt and p27Kip1. β-actin was used as loading control. The blot for NRG1-CRD was performed on cell supernatants and loading corrected to the number of cells present at the time of media collection in the various treatment groups. Data are representative of at least three independent experiments.